Darbà, JosepAscanio, Meritxell2020-06-092020-06-092019-032211-8837https://hdl.handle.net/2445/164980In the European Union companies only need to demonstrate that the risk-benefit balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a comparison with available treatments, a cost-effectiveness analysis and the place in the therapy of the new drug are not required. Therefore, it is necessary to carry out these analyses in an additional study. In Spain there is no national government agency, which conducts a centralized evaluation and makes decisions on funding and are the Pharmacy and Therapeutics committees that take mandatory decisions for the entire region.10 p.application/pdfengcc-by-nc-nd (c) Fellowship of Postgraduate Medicine, 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esTerapèuticaAnàlisi enzimàticaLisosomesFarmacologiaTherapeuticsEnzymatic analysisLysosomesPharmacologyinfo:eu-repo/semantics/article6911122020-06-09info:eu-repo/semantics/openAccess